Moderna (MRNA) Receivables - Other (2017 - 2026)

Moderna (MRNA) has 10 years of Receivables - Other data on file, last reported at $39.0 million in Q1 2026.

• On a quarterly basis, Receivables - Other fell 26.42% year-over-year to $39.0 million in Q1 2026; TTM through Mar 2026 was $39.0 million, a 26.42% decrease from a year earlier, with the FY2025 full-year figure at $42.0 million, down 28.81% from the prior year.
• Receivables - Other for Q1 2026 stood at $39.0 million, down from $42.0 million in the prior quarter.
• Over the last five years, Receivables - Other for MRNA reached as high as $69.0 million in Q1 2023 and fell as low as $36.0 million in Q1 2022.
• Historically, Receivables - Other has averaged $52.8 million across 5 years, with a median of $54.0 million in 2022.
• Across the five-year window, Receivables - Other surged 350.0% in 2022 and fell 28.81% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $61.0 million in 2022, then declined by 3.28% to $59.0 million in 2023, then changed by 0.0% to $59.0 million in 2024, then decreased by 28.81% to $42.0 million in 2025, then slipped by 7.14% to $39.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $39.0 million in Q1 2026, $42.0 million in Q4 2025, and $40.0 million in Q3 2025.